Compare KLTR & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | STTK |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | 563 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.4M | 119.0M |
| IPO Year | 2021 | 2020 |
| Metric | KLTR | STTK |
|---|---|---|
| Price | $1.65 | $3.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $4.00 |
| AVG Volume (30 Days) | 360.8K | ★ 392.9K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | $1,000,000.00 |
| Revenue This Year | $3.10 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $1.36 | $0.69 |
| 52 Week High | $2.82 | $3.38 |
| Indicator | KLTR | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 67.21 |
| Support Level | $1.59 | $2.82 |
| Resistance Level | $1.71 | $3.30 |
| Average True Range (ATR) | 0.10 | 0.24 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 58.57 | 74.76 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.